Aberdeen Group
FUSN

Aberdeen Group’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Aberdeen Group’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,697
Closed -$209K – 978
2023
Q4 		$209K Buy
+21,697
New +$105K ﹤0.01% 938

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aberdeen Group's FUSN Position: Q1 2024 in Review

Aberdeen Group sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 21,697 shares — an estimated $209K sold.

Aberdeen Group first reported a position in FUSN in Q4 2023 and held it in 1 quarter. The position peaked at $209K in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Aberdeen Group reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Aberdeen Group sold 21,697 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $209K.
  • Aberdeen Group first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2023 and held it in 1 quarter.
  • Aberdeen Group's Fusion Pharmaceuticals Inc. Common Shares position peaked at $209K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Aberdeen Group's 13F filing for Q1 2024, filed 9 May 2024.